0001127602-24-020270.txt : 20240710 0001127602-24-020270.hdr.sgml : 20240710 20240710120448 ACCESSION NUMBER: 0001127602-24-020270 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240708 FILED AS OF DATE: 20240710 DATE AS OF CHANGE: 20240710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farrell Michael J. CENTRAL INDEX KEY: 0001485164 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 241109278 MAIL ADDRESS: STREET 1: C/O REMED INC STREET 2: 9001 SPECTRUM CTR. BLVD. CITY: SAN DIEGO, STATE: CA ZIP: 92123 FORMER NAME: FORMER CONFORMED NAME: Farrell Michael DATE OF NAME CHANGE: 20100224 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-07-08 0000943819 RESMED INC RMD 0001485164 Farrell Michael J. RESMED INC. 9001 SPECTRUM CENTER BLVD SAN DIEGO CA 92123 1 Chief Executive Officer 1 ResMed Common Stock 2024-07-08 4 M 0 14683 84.98 A 455482 D ResMed Common Stock 2024-07-08 4 S 0 14683 192.9667 D 440799 D ResMed Common Stock 0 I Lisette and Michael Farrell Foundation ResMed Common Stock 4090 I Lisette and Michael Farrell Family Trust ResMed Common Stock Options 84.98 2024-07-08 4 M 0 14683 0 D 2018-11-11 2024-11-16 ResMed Common Stock 14683 58732 D The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024. This transaction was executed in multiple trades at prices ranging from $192.03 - $194.73. The price reported above reflects the weighted average sale price. Represents date options first became exercisable. Options vest 1/3 per year. Michael J. Farrell, Chief Executive Officer 2024-07-09